Affordable Access

Access to the full text

Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia

Authors
  • Ladikou, E. E.1, 2
  • Sivaloganathan, H.1
  • Pepper, A.1
  • Chevassut, T.1, 2
  • 1 University of Sussex, Brighton, BN1 9PS, UK , Brighton (United Kingdom)
  • 2 Royal Sussex County Hospital, Brighton, BN2 5BE, UK , Brighton (United Kingdom)
Type
Published Article
Journal
Current Oncology Reports
Publisher
Springer-Verlag
Publication Date
Feb 11, 2020
Volume
22
Issue
3
Identifiers
DOI: 10.1007/s11912-020-0885-0
Source
Springer Nature
Keywords
License
Green

Abstract

Purpose of ReviewAcute myeloid leukaemia (AML) is a heterogeneous malignancy for which treatment options remain suboptimal. It is clear that a greater understanding of the biology of the AML niche will enable new therapeutic strategies to be developed in order to improve treatment outcomes for patients.Recent FindingsRecent evidence has highlighted the importance of the bone marrow microenvironment in protecting leukaemia cells, and in particular leukaemic stem cells from chemotherapy-induced cell death. This includes mesenchymal stem cells supporting growth and preventing apoptosis, and altered action and secretion profiles of other niche components including adipocytes, endothelial cells and T cells.SummaryHere, we provide a detailed overview of the current understanding of the AML bone marrow microenvironment. Clinical trials of agents that mobilise leukaemic stem cells from the bone marrow are currently ongoing and show early promise. Future challenges will involve combining these novel therapies targeted at the AML niche with conventional chemotherapy treatment.

Report this publication

Statistics

Seen <100 times